Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Operations: 2012-2025

Historic Cash from Operations for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$6.5 million.

  • Enanta Pharmaceuticals' Cash from Operations rose 37.61% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.3 million, marking a year-over-year increase of 75.53%. This contributed to the annual value of -$19.3 million for FY2025, which is 75.53% up from last year.
  • Enanta Pharmaceuticals' Cash from Operations amounted to -$6.5 million in Q3 2025, which was down 137.07% from $17.5 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Cash from Operations high stood at $17.5 million for Q2 2025, and its period low was -$35.6 million during Q4 2022.
  • Its 3-year average for Cash from Operations is -$15.0 million, with a median of -$14.8 million in 2024.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Cash from Operations slumped by 557.44% in 2021 and then skyrocketed by 218.48% in 2025.
  • Enanta Pharmaceuticals' Cash from Operations (Quarterly) stood at -$13.3 million in 2021, then tumbled by 168.56% to -$35.6 million in 2022, then climbed by 29.89% to -$25.0 million in 2023, then soared by 32.76% to -$16.8 million in 2024, then surged by 37.61% to -$6.5 million in 2025.
  • Its Cash from Operations was -$6.5 million in Q3 2025, compared to $17.5 million in Q2 2025 and -$13.5 million in Q1 2025.